Principal Financial Group
TVTX icon

Principal Financial Group’s Travere Therapeutics TVTX Stock Holding History

Principal Financial Group’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$388K Buy
+6,836
New +$303K ﹤0.01% 2028
2024
Q3 		– Sell
-10,288
Closed -$84.6K – 2406
2024
Q2 		$84.6K Sell
10,288
-8,317
-45% -$56K ﹤0.01% 2235
2024
Q1 		$143K Buy
18,605
+243
+1% +$2.05K ﹤0.01% 2228
2023
Q4 		$165K Buy
18,362
+157
+0.9% +$1.14K ﹤0.01% 2196
2023
Q3 		$163K Sell
18,205
-177
-1% -$2.5K ﹤0.01% 2198
2023
Q2 		$282K Buy
18,382
+2,452
+15% +$44.6K ﹤0.01% 2093
2023
Q1 		$358K Sell
15,930
-903
-5% -$19.2K ﹤0.01% 2048
2022
Q4 		$354K Sell
16,833
-15,914
-49% -$337K ﹤0.01% 2061
2022
Q3 		$807K Sell
32,747
-29,298
-47% -$757K ﹤0.01% 1872
2022
Q2 		$1.5M Buy
+62,045
New +$1.56M ﹤0.01% 1851
2022
Q1 		– Sell
-7,267
Closed -$226K – 2601
2021
Q4 		$226K Sell
7,267
-4,175
-36% -$118K ﹤0.01% 2325
2021
Q3 		$277K Sell
11,442
-1,856
-14% -$34.1K ﹤0.01% 2332
2021
Q2 		$194K Sell
13,298
-9,815
-42% -$194K ﹤0.01% 2481
2021
Q1 		$577K Buy
23,113
+210
+0.9% +$5.8K ﹤0.01% 2119
2020
Q4 		$625K Buy
+22,903
New +$535K ﹤0.01% 2056
2019
Q2 		– Sell
-19,153
Closed -$433K – 2278
2019
Q1 		$433K Buy
19,153
+501
+3% +$11.1K ﹤0.01% 1969
2018
Q4 		$422K Sell
18,652
-8,507
-31% -$212K ﹤0.01% 1953
2018
Q3 		$780K Buy
27,159
+8,144
+43% +$233K ﹤0.01% 1888
2018
Q2 		$518K Sell
19,015
-2,213
-10% -$58.9K ﹤0.01% 1959
2018
Q1 		$475K Buy
21,228
+1,950
+10% +$46.4K ﹤0.01% 1947
2017
Q4 		$406K Sell
19,278
-2,056
-10% -$47K ﹤0.01% 2005
2017
Q3 		$531K Hold
21,334
– – ﹤0.01% 1920
2017
Q2 		$414K Buy
21,334
+8,596
+67% +$156K ﹤0.01% 1986
2017
Q1 		$235K Hold
12,738
– – ﹤0.01% 2064
2016
Q4 		$241K Buy
+12,738
New +$261K ﹤0.01% 2062
2015
Q3 		– Sell
-6,027
Closed -$200K – 2221
2015
Q2 		$200K Buy
+6,027
New +$165K ﹤0.01% 2047

Other funds holding TVTX

JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Principal Financial Group's TVTX Position: Q2 2026 in Review

Principal Financial Group opened a new position in Travere Therapeutics (TVTX) in Q2 2026: 6,836 shares worth $388K. The stake represents ﹤0.01% of the portfolio and ranks #2028 among its holdings. This is a return to the name: Principal Financial Group previously reported a position in TVTX as recently as Q2 2024.

Principal Financial Group first reported a position in TVTX in Q2 2015 and has held it in 26 quarters since. The position peaked at $1.5M in Q2 2022. 321 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Principal Financial Group held 6,836 shares of Travere Therapeutics worth $388K as of Q2 2026.
  • Travere Therapeutics was a new Principal Financial Group position in Q2 2026.
  • Travere Therapeutics made up ﹤0.01% of Principal Financial Group's portfolio in Q2 2026, its #2028 holding.
  • Principal Financial Group first reported a position in Travere Therapeutics in Q2 2015 and has held it in 26 quarters since.
  • Principal Financial Group's Travere Therapeutics position peaked at $1.5M in Q2 2022.
  • 321 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Principal Financial Group's 13F filing for Q2 2026, filed 4 Aug 2026.